CV Sciences (CVSI) Return on Capital Employed (2011 - 2026)
CV Sciences (CVSI) posted Return on Capital Employed of 48.07% for Q1 2026, down 102.37% sequentially from 23.76% in Q4 2025, and up 1207.0% YoY from 3.68% in Q1 2025.
CV Sciences (CVSI) Return on Capital Employed (2011 - 2026) Analysis & Trends
CV Sciences has reported Return on Capital Employed for 16 years, with the latest figure at 48.07% in Q1 2026.
- Quarterly Return on Capital Employed rose 1207.0% year-over-year to 48.07% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 48.07% (up 1207.0% YoY) and the FY2025 annual result came in at 19.23%, up 7000.0% from the prior year.
- Return on Capital Employed fell to 48.07% in Q1 2026 per CVSI's latest filing, from 23.76% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 159.07% in Q3 2024 and troughed at 1062.37% in Q4 2022.
- A 5-year average of 152.52% and a median of 48.07% in 2026 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed tumbled 77312 bps in 2022, then jumped 116399 bps in 2023.
- Over 5 years, Return on Capital Employed stood at 1062.37% in 2022, then jumped by 110 bps to 101.62% in 2023, then gained by 9 bps to 110.89% in 2024, then tumbled by 121 bps to 23.76% in 2025, then tumbled by 102 bps to 48.07% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 48.07%, 23.76%, and 38.75% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | CV Sciences | 4.10 Mn | 3.84 Mn | 1.45 Mn | -57.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -57.73% |
| Mar 31, 2026 | -48.07% |
| Dec 31, 2025 | -23.76% |
| Sep 30, 2025 | -38.75% |
| Jun 30, 2025 | -51.48% |
| Mar 31, 2025 | -60.15% |
| Dec 31, 2024 | 110.89% |
| Sep 30, 2024 | 159.07% |
| Jun 30, 2024 | -95.61% |
| Mar 31, 2024 | -105.15% |
| Dec 31, 2023 | 101.62% |
| Sep 30, 2023 | 57.41% |
| Jun 30, 2023 | 34.59% |
| Mar 31, 2023 | 7.35% |
| Dec 31, 2022 | -1,062.37% |
| Sep 30, 2022 | -701.21% |
| Jun 30, 2022 | -452.92% |
| Mar 31, 2022 | -424.28% |
| Dec 31, 2021 | -289.26% |
| Sep 30, 2021 | -142.30% |